GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Price-to-Owner-Earnings

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Price-to-Owner-Earnings : (As of Jun. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Price-to-Owner-Earnings?

As of today (2024-06-07), Pathfinder Cell Therapy's share price is $0.0001. Pathfinder Cell Therapy does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Pathfinder Cell Therapy's Price-to-Owner-Earnings or its related term are showing as below:


PFND's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-07), Pathfinder Cell Therapy's share price is $0.0001. Pathfinder Cell Therapy's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 was $0.00. Therefore, Pathfinder Cell Therapy's PE Ratio for today is N/A.

As of today (2024-06-07), Pathfinder Cell Therapy's share price is $0.0001. Pathfinder Cell Therapy's EPS without NRI for the trailing twelve months (TTM) ended in was $0.00. Therefore, Pathfinder Cell Therapy's PE Ratio without NRI for today is N/A.


Pathfinder Cell Therapy Price-to-Owner-Earnings Historical Data

The historical data trend for Pathfinder Cell Therapy's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy Price-to-Owner-Earnings Chart

Pathfinder Cell Therapy Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pathfinder Cell Therapy Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pathfinder Cell Therapy's Price-to-Owner-Earnings

For the Biotechnology subindustry, Pathfinder Cell Therapy's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pathfinder Cell Therapy's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pathfinder Cell Therapy's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pathfinder Cell Therapy's Price-to-Owner-Earnings falls into.



Pathfinder Cell Therapy Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pathfinder Cell Therapy's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0001/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pathfinder Cell Therapy  (OTCPK:PFND) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Pathfinder Cell Therapy Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Traded in Other Exchanges
N/A
Address
12 Bow Street, Cambridge, MA, USA, 02138
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Executives
John J Alam director 130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines